APUS Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
12.2M
+73.1%
7.0M
+281.7%
1.8M
-30.8%
2.7M
R&D
901.1K
+149.6%
361.1K
-41.7%
619.7K
-4.9%
651.8K
SG&A
11.3M
+69.0%
6.7M
+445.4%
1.2M
-39.1%
2.0M
Operating Income
-12185694
-73.1%
-7040051
-281.7%
-1844239
+30.8%
-2663904
EBITDA
-12165650
-72.9%
-7036066
-281.8%
-1842750
+30.8%
-2663672
Net Income
-35059852
-2934.7%
-1155292
+35.1%
-1781255
+33.1%
-2662193
EPS (Basic)
$-2.26
-7433.3%
$-0.03
+97.9%
$-1.40
+46.2%
$-2.60
EPS (Diluted)
$-2.26
-7433.3%
$-0.03
+97.9%
$-1.40
+46.2%
$-2.60
Shares (Diluted)
15.5M
-53.5%
33.3M
+2550.2%
1.3M
+21.3%
1.0M
Apimeds Pharmaceuticals US (APUS) โ€” Financials